Arcutis Biotherapeutics delivered a strong Q4 2025, with $127.5M in revenue and a GAAP EPS beat, driven by Zoryve's rapid ...

Maintenance therapy with subcutaneous imsidolimab allowed all treated patients to remain flare-free throughout the GEMINI-2 study period.

Imsidolimab is a monoclonal antibody that inhibits interleukin-36 receptor signaling and is administered intravenously.

Planning for phase 1/2 clinical trial initiation in Australia utilizing CYWC628 to treat diabetic foot ulcers in the first half of 2026Improved ...

Researchers identify a neural circuit in the lateral hypothalamus that suppresses itch during acute stress, offering new insights into chronic itch management.

In adults with psoriasis, ustekinumab showed the highest drug survival rate in biologic-naive patients but had reduced effectiveness in biologic-experienced patients.

A common strep throat infection can trigger guttate psoriasis by altering the behavior of key immune cells, according to a new study from Karolinska Institutet published in eBioMedicine. The findings ...

Why aren't we talking about it more?

The results of 2 recent clinical trials combining the GLP-1 drug and the biologic reinforce the benefits of treating obesity and inflammation together.

"Understanding biologic therapy trajectories in Medicaid is important, given its distinct formulary restrictions and patient demographics," they concluded. "Interventions must not only address access ...

Combination ixekizumab plus tirzepatide outperformed ixekizumab monotherapy for the treatment of both psoriasis and overweight or obesity, according to topline results announced by Eli ...

The total net revenues of AbbVie's Rinvoq and Skyrizi were about $25.87 billion in 2025, up 46.2% from 2024. Read why ABBV ...